I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Dotake, Yoichi
11
results:
Search for persons
X
Format
Online (11)
Mediatypes
Articles (Online) (4)
OpenAccess-fulltext (7)
Sorted by: Relevance
Sorted by: Year
?
1
Group III secreted phospholipase A2‐driven lysophospholipid..:
Hamu‐Tanoue, Asako
;
Takagi, Koichi
;
Taketomi, Yoshitaka
...
The FASEB Journal. 38 (2024) 2 - p. , 2024
Link:
https://doi.org/10.1096/..
?
2
Severe asthma remaining well‐controlled after mepolizumab d..:
Matsuyama, Takahiro
;
Tomioka, Yuya
;
Matsuyama, Hiromi
...
Respirology Case Reports. 11 (2023) 6 - p. , 2023
Link:
https://doi.org/10.1002/..
?
3
The Functional Role of Group 2 Innate Lymphoid Cells in Ast..:
Matsuyama, Takahiro
;
Machida, Kentaro
;
Mizuno, Keiko
...
Biomolecules. 13 (2023) 6 - p. 893 , 2023
Link:
https://doi.org/10.3390/..
?
4
The Therapeutic Potential for Targeting Group 2 Innate Lymp..:
Matsuyama, Takahiro
;
Matsuyama, Hiromi
;
Dotake, Yoichi
...
Frontiers in Immunology. 13 (2022) - p. , 2022
Link:
https://doi.org/10.3389/..
?
5
Severe asthma remaining well‐controlled after mepolizumab d..:
Matsuyama, Takahiro
;
Tomioka, Yuya
;
Matsuyama, Hiromi
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173049/. , 2023
Link:
http://www.ncbi.nlm.nih...
?
6
The Functional Role of Group 2 Innate Lymphoid Cells in Ast..:
Matsuyama, Takahiro
;
Machida, Kentaro
;
Mizuno, Keiko
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296683/. , 2023
Link:
http://www.ncbi.nlm.nih...
?
7
The Therapeutic Potential for Targeting Group 2 Innate Lymp..:
Matsuyama, Takahiro
;
Matsuyama, Hiromi
;
Dotake, Yoichi
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327784/. , 2022
Link:
http://www.ncbi.nlm.nih...
?
8
The Functional Role of Group 2 Innate Lymphoid Cells in Ast..:
Takahiro Matsuyama
;
Kentaro Machida
;
Keiko Mizuno
...
Molecular Medicine. , 2023
Link:
https://doi.org/10.3390/..
?
9
The Functional Role of Group 2 Innate Lymphoid Cells in Ast..:
Takahiro Matsuyama
;
Kentaro Machida
;
Keiko Mizuno
...
https://www.mdpi.com/2218-273X/13/6/893. , 2023
Link:
https://doi.org/10.3390/..
?
10
Severe asthma remaining well‐controlled after mepolizumab d..:
Takahiro Matsuyama
;
Yuya Tomioka
;
Hiromi Matsuyama
...
https://doi.org/10.1002/rcr2.1158. , 2023
Link:
https://doi.org/10.1002/..
?
11
The Therapeutic Potential for Targeting Group 2 Innate Lymp..:
Takahiro Matsuyama
;
Hiromi Matsuyama
;
Yoichi Dotake
...
https://www.frontiersin.org/articles/10.3389/fimmu.2022.930862/full. , 2022
Link:
https://doi.org/10.3389/..
1-11
